一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (624k)
Article in Japanese

Case Report

A case of lung cancer with rearranged ALK and wild-type EGFR responding to erlotinib

Kentarou Itoua  Osamu Hatajia  Fumihiko Komadab  Ebihara Aikoc  Hiroyasu Kobayashid  Osamu Taguchid 

aDivision of Respiratory Medicine, Matsusaka Municipal Hospital
bDivision of Internal Medicine, Matsusaka Municipal Hospital
cDivision of Internal Medicine, Yamamoto General Hospital
dDivision of Respiratory Medicine, Mie University Hospital

ABSTRACT

Anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma is generally known to be resistant to erlotinib. We report a case of lung adenocarcinoma with a rearranged ALK and wild-type epidermal growth factor receptor (EGFR) that had good response to the treatment of erlotinib. A 46-year-old man was admitted to our hospital due to severe hypoxemia. Chest CT showed a tumor shadow in the right lung with multiple small nodules. We performed fiberoptic bronchoscopy and diagnosed lung adenocarcinoma (cT4N3M1a, Stage IV). EGFR mutations were analyzed by using polymerase chain reaction (PCR) method, resulted in wild-type EGFR. Another assessment revealed the positive ALK rearrangement, using the methods of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The patient was treated with cisplatin (CDDP) and gemcitabine (GEM); however, the lung tumor was enlarged. After failure of the treatment with docetaxel (DTX), erlotinib was administered as the third-line chemotherapy, leading to the decreased carcinoembryonic antigen (CEA) levels and the drastic reduction of tumor size. Despite the favorable response to this drug, the tumor was again enlarged; thus chemotherapy using bevacizumab was started and continued until tumor regrowth was observed a year later. Erlotinib was then readministered to this patient, resulting in the recovered ability of this drug to reduce the tumor size. The effect has been surprisingly lasting for eight months on the inhibition of tumor growth.

KEYWORDS

Erlotinib  Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase  Epidermal growth factor receptor  Re-treatment with erlotinib 

Received 7 Mar 2012 / Accepted 9 May 2012

AJRS, 1(7): 604-608, 2012

Google Scholar